Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 45% Improvement Relative Risk c19early.org/d Singh et al. NCT04952857 Shade-S Vitamin D RCT LATE Favors vitamin D Favors control
Single, High Dose Vitamin D Supplementation in Vitamin D Deficient Severe COVID-19: Randomized, Double-Blind, Placebocontrol Study (Shade-S)
Singh et al., Abstracts Criticare - IJCCM2022, Indian J. Crit. Care Med., doi:10.5005/ijccm-26-S1-S1, Shade-S, NCT04952857 (history)
1 Jun 2022    Source   PDF   Share   Tweet
RCT 90 vitamin D deficient moderate/severe COVID-19 ARDS patients in India, showing lower mortality with vitamin D treatment. 600,000IU nanoformulation cholecalciferol. Minimal information is currently available.
risk of death, 45.0% lower, RR 0.55, p = 0.046, treatment 11 of 45 (24.4%), control 20 of 45 (44.4%), NNT 5.0.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in the after exclusion results of meta analysis: minimal details provided.
Singh et al., 1 Jun 2022, Double Blind Randomized Controlled Trial, placebo-controlled, India, peer-reviewed, 10 authors, dosage 600,000IU single dose, trial NCT04952857 (history) (Shade-S).
Contact: ajay. ydv2509@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit